Precigen: PAPZIMEOS Is Delivering For This Under-The-Radar Biotech [Seeking Alpha]
Precigen, Inc. (PGEN)
Last precigen, inc. earnings: 3/2 04:05 pm
Check Earnings Report
Company Research
Source: Seeking Alpha
PGEN's rapid US launch, strong payer coverage, and physician adoption could suggest blockbuster status by 2030. Management targets cash flow breakeven this year, while the analyst consensus is for $98 million in FY26 revenues. Risks include a higher valuation post-rally & competitive threats from Inovio, but PGEN's current traction and its impressive AdenoVerse pipeline offer significant upside. Jian Fan/iStock via Getty Images Since I last reported on Precigen ( PGEN ) in early July, the stock is up 185%. A lot has transpired: the company received FDA approval for its lead asset for Recurrent Respiratory Papillomatosis (RRP). The This article was written by Analyst's Disclosure: I/we have a beneficial long position in the shares of PGEN either through stock ownership, options, or other derivatives. I wrote this article myself, and it expresses my own opinions. I am not receiving compensation for it (other than from Seeking Alpha). I have no business relationship with a
Show less
Read more
Impact Snapshot
Event Time:
PGEN
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
PGEN alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
PGEN alerts
High impacting Precigen, Inc. news events
Weekly update
A roundup of the hottest topics
PGEN
News
- Precigen (NASDAQ:PGEN) was downgraded by analysts at Zacks Research from a "hold" rating to a "strong sell" rating.MarketBeat
- New Expert Consensus Published in The Laryngoscope Recommends PAPZIMEOS (zopapogene imadenovec) as the New Standard of Care First-Line Treatment for Adults with Recurrent Respiratory PapillomatosisPR Newswire
- Precigen Showcases Rapid Commercialization Momentum and Growing Market Adoption of First-and-Only FDA-Approved Therapy for RRP at the 44th Annual J.P. Morgan Healthcare ConferencePR Newswire
- Precigen to Present at the 44th Annual J.P. Morgan Healthcare Conference [Yahoo! Finance]Yahoo! Finance
- Precigen to Present at the 44th Annual J.P. Morgan Healthcare ConferencePR Newswire
PGEN
Earnings
- 11/13/25 - Miss
PGEN
Sec Filings
- 1/23/26 - Form SCHEDULE
- 12/22/25 - Form 4
- 12/22/25 - Form 144
- PGEN's page on the SEC website